Amneal Pharmaceuticals(US:AMRX)2026-02-27 21:19Debt and Financial Obligations - As of December 31, 2025, the company had approximately $2.7 billion in total indebtedness, with expected principal payments of $21.0 million on the Term Loan Due 2032 during 2026[232]. - The company anticipates making interest payments totaling $193.9 million in 2026 related to the Term Loan Due 2032 and Senior Notes Due 2032[232]. - The company has $2.69 billion in total debt as of December 31, 2025, including a Term Loan Due 2032 of $2.09 billion and Senior Notes Due 2032 of $600 million[390]. - The fair value of the Term Loan Due 2032 and Senior Notes Due 2032 was estimated at $2.12 billion and $633 million respectively as of December 31, 2025[390]. - The company does not anticipate paying any cash dividends in the foreseeable future, focusing instead on retaining earnings for business growth[266]. Regulatory and Economic Environment - The company faces increased regulatory oversight and economic uncertainties in international markets, particularly in India and Ireland, which could adversely affect its operations[239]. - Global economic conditions and government-mandated pricing actions may exert pressure on product pricing and market access, potentially harming the company's financial performance[243]. - The company is subject to potential tax liabilities in multiple jurisdictions, which could increase due to changes in tax laws or challenges from tax authorities[245]. - The implementation of the OECD's Pillar Two proposal, which includes a global minimum tax rate of at least 15%, may affect the company's tax exposure, particularly in Ireland[246]. Asset and Impairment Risks - The company may face significant impairment charges on goodwill and intangible assets if they are determined to be impaired, adversely affecting its results of operations[251]. - Generic pharmaceuticals are experiencing regular and increasing price erosion, impacting revenues and profits in the Affordable Medicines and Specialty segments[252]. Financial Management and Investments - The company may pursue acquisitions or investments in complementary businesses, which could increase leverage or dilute equity holders if financed through debt or equity[242]. - As of December 31, 2025, the company recorded TRA expenses of $6.6 million, $50.7 million, and $3.1 million for the years 2025, 2024, and 2023 respectively[254]. - The TRA liability as of December 31, 2025 and 2024 was $57.5 million and $53.9 million respectively, with a potential unrecorded contingent TRA liability of $129.1 million[254]. Interest Rate and Currency Exposure - The company is exposed to foreign exchange rate fluctuations, particularly with the Euro and Indian Rupee, impacting cash flow and earnings[387]. - As of December 31, 2025, the company had variable rate debt of $2.09 billion, down from $2.48 billion in 2024[390]. - The company terminated its existing interest rate swap and entered into a new interest rate lock agreement with a notional value of $650.0 million[391]. - The fixed interest rate for the new interest rate lock agreement is 3.1636%, while receiving one-month SOFR with a 0.50% floor through May 6, 2030[391]. - As of December 31, 2025, the fair value of the interest rate swap asset was $5.8 million[391]. - A hypothetical 100 basis point increase in the forward one-month SOFR curve could increase the fair value of the interest rate swap asset by $24.6 million[391]. - Conversely, a hypothetical 100 basis point decrease in the forward one-month SOFR curve could decrease the fair value of the interest rate swap asset by $24.4 million[391]. - A hypothetical 100 basis point increase or decrease in interest rates would affect the company's annual interest expense by approximately $20.9 million[392]. Inflation and Cost Management - The company expects no material impact from inflation for the year ending December 31, 2026, although rising costs could adversely affect future operating results[388]. - Cash equivalents are held in highly rated money market funds, with no short-term investments reported as of December 31, 2025[383].